Albumin in Burn Shock Resuscitation: A Meta-Analysis of Controlled Clinical Studies. by Navickis, Roberta et al.
UC Davis
UC Davis Previously Published Works
Title
Albumin in Burn Shock Resuscitation: A Meta-Analysis of Controlled Clinical 
Studies.
Permalink
https://escholarship.org/uc/item/9gc8h4jf
Journal
Journal of Burn Care and Research, 37(3)
Authors
Navickis, Roberta
Greenhalgh, David
Wilkes, Mahlon
Publication Date
2016-05-01
DOI
10.1097/BCR.0000000000000201
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
e268
Although fluid resuscitation is the foundation of acute 
burn care, the optimal type, timing, and amount of 
fluid for burn shock remains inadequately investi-
gated. Early burn resuscitation formulas of the 1940s 
and 1950s incorporated colloids, usually in the form 
of albumin-containing blood products1,2 but also puri-
fied albumin.3 Unacceptably high rates of viral hepa-
titis transmission discouraged the continued use of 
plasma preparations available during that period, how-
ever.4 By contrast, no case of viral disease transmission 
has ever been identified for licensed albumin or albu-
min contained in other licensed products, according to 
the US Food and Drug Administration.5 In addition 
to concern about viral disease transmission, the sub-
sequent introduction of crystalloid-only formulas was 
prompted by an increasing focus on the role of extra-
vascular sodium deficiency in burn shock.6
The commonly used Parkland and modified Brooke 
formulas using crystalloid in the form of lactated Ring-
er’s solution have remained unchanged since their 
introduction in the 1970s.7 In the first 24 hours after 
a burn, the Parkland formula calls for 4 ml·kg−1 crys-
talloid per percent TBSA (%TBSA) burned and the 
modified Brooke formula for 2 ml·kg−1 per %TBSA.
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Critical appraisal of outcomes after burn shock resuscitation with albumin has previously 
been restricted to small relatively old randomized trials, some with high risk of bias. 
Extensive recent data from nonrandomized studies assessing the use of albumin can 
potentially reduce bias and add precision. The objective of this meta-analysis was 
to determine the effect of burn shock resuscitation with albumin on mortality and 
morbidity in adult patients. Randomized and nonrandomized controlled clinical studies 
evaluating mortality and morbidity in adult patients receiving albumin for burn shock 
resuscitation were identified by multiple methods, including computer database searches 
and examination of journal contents and reference lists. Extracted data were quantitatively 
combined by random-effects meta-analysis. Four randomized and four nonrandomized 
studies with 688 total adult patients were included. Treatment effects did not differ 
significantly between the included randomized and nonrandomized studies. Albumin 
infusion during the first 24 hours showed no significant overall effect on mortality. 
However, significant statistical heterogeneity was present, which could be abolished by 
excluding two studies at high risk of bias. After those exclusions, albumin infusion was 
associated with reduced mortality. The pooled odds ratio was 0.34 with a 95% confidence 
interval of 0.19 to 0.58 (P < .001). Albumin administration was also accompanied by 
decreased occurrence of compartment syndrome (pooled odds ratio, 0.19; 95% confidence 
interval, 0.07–0.50; P < .001). This meta-analysis suggests that albumin can improve 
outcomes of burn shock resuscitation. However, the scope and quality of current evidence 
are limited, and additional trials are needed. (J Burn Care Res 2016;37:e268–e278)
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An increasingly recognized concern is that many 
patients are found to receive considerably more resus-
citation fluid than predicted by the formulas.8 This 
phenomenon was termed “fluid creep” by Pruitt in 
2000, and excessive resuscitation has emerged as a 
significant problem in modern burn care.8,9 Numer-
ous reports document that the majority of patients 
with major burns are exceeding the predicted amount 
of acute care resuscitation fluid.10–17 In a 2007 U.S. 
multicenter study of patients with major burns, fluid 
in excess of the predicted volume was accompanied 
by increased odds of pneumonia, with an odds ratio 
(OR) of 1.92, bloodstream infections (OR, 2.33), 
adult respiratory distress syndrome (OR, 1.55), mul-
tiorgan failure (OR, 1.49), and death (OR, 1.74).18
A major complication attributable to over-resuscita-
tion in burn patients is compartment syndrome of the 
abdomen or extremities resulting from massive edema 
in both burned and unburned tissue.11,19–22 Large-
volume fluid resuscitation in patients with major burns 
increases the risk of intraabdominal hypertension 
and consequent abdominal compartment syndrome 
(ACS). Generally, ACS is encountered in patients with 
extensive burns of approximately 50% TBSA or more, 
often with concomitant inhalation injury.23 ACS can 
significantly worsen the prognosis of burn patients.
The primary goal of resuscitation is to restore and 
preserve tissue perfusion. Colloids by virtue of their 
oncotic properties can better maintain intravascular 
volume than crystalloids, and thus reduce fluid vol-
ume demands. Yet, the question of whether colloids 
can improve outcomes of burn shock resuscitation 
remains unsettled. In an international survey of burn 
shock resuscitation practices, approximately half of 
respondents administered colloid during the first 24 
hours.24 The colloids predominantly used were puri-
fied albumin and fresh frozen plasma (FFP). Present 
at a concentration of 4.09 g·dL−1, albumin is the pre-
dominant protein in FFP, accounting for more than 
75% of its colloid osmotic pressure.25
Definitive large-scale randomized trials investigat-
ing the use of albumin for burn shock resuscitation 
have yet to be conducted. Meta-analysis can be of 
value in establishing the current state of knowledge 
and informing the design of future trials. While theo-
retically randomized trials should guarantee balance 
between treatment groups and minimize distortions 
arising from the placebo effect, the currently available 
randomized trials examining albumin infusion for burn 
shock resuscitation are few in number, small in size, and 
prone to bias, for instance, resulting from lack of blind-
ing and imbalances in baseline risk. A series of larger 
and more recent nonrandomized controlled studies 
can potentially reduce bias and increase precision.26 
As a general principle, the inclusion of both random-
ized and nonrandomized studies in meta-analyses has 
been advocated,27 and such an approach appears to be 
particularly appropriate in light of currently available 
evidence on albumin infusion for burn shock resuscita-
tion. We here describe such a meta-analysis.
METHODS
Inclusion Criteria
Controlled clinical studies comparing purified human 
albumin with crystalloid for burn shock resuscitation 
of adult patients were eligible for inclusion. Studies of 
postresuscitation albumin supplementation for hypo-
albuminemia were not considered. Data on mortality 
and/or morbidity must have been available. Safeguards 
against bias arising from imbalances in baseline risk of 
poor outcome must have been implemented either 
through random allocation to treatment or, in the case 
of nonrandomized studies, by adjustment for observed 
imbalances with multivariate statistical methods. No 
language or time period restrictions were imposed.
Search Techniques
Published and unpublished studies conforming to 
the above inclusion criteria were sought by a vari-
ety of methods, including computer searches of bib-
liographic databases (MEDLINE and EMBASE), 
the Cochrane Library, meeting abstract databases 
and other Internet-resident information resources. 
Online and hard copy journal contents were perused. 
Reference lists were examined.
Data Extraction
Two investigators independently extracted data from the 
reports of included studies. Differences in interpretation 
were resolved by discussion. Extracted data consisted of: 
study year, locale, and design; numbers of study centers, 
patients, deaths, and complications; resuscitation fluid 
regimens compared; age; %TBSA burned; inhalation 
injury; and imbalances in baseline risk factors.
Statistical Analysis
The primary outcome measure was the OR for mortal-
ity and particular types of complications. The pooled 
OR for included studies and its 95% confidence 
interval (CI) were computed under a random-effects 
model.28 Heterogeneity, that is, variability of effect size 
greater than expected for a homogeneous population 
of studies, was evaluated by Cochran Q test and the I2 
statistic.29 Differences in effect between randomized 
and nonrandomized studies were determined by test 
 Journal of Burn Care & Research
e270  Navickis, Greenhalgh, and Wilkes May/June 2016
of interaction.30 Publication bias was assessed by linear 
regression of standardized effect vs precision.31 Qual-
ity assessment of randomized studies included three 
validated criteria: randomization method, allocation 
concealment, and blinding.32
RESULTS
Included Studies
Through the search process 135 candidate study 
reports were identified (Figure 1). On screening of 
the abstracts, 31 of the reports were excluded, most 
often because they were review articles without orig-
inal data. The full text of the other 104 articles was 
examined in detail. At that stage 96 additional reports 
were excluded, again most frequently because of lack 
of original data.
The remaining eight studies, four random-
ized, and four nonrandomized, with a total of 688 
patients were included.33–40 One randomized study 
involved both pediatric and adult patients,33 and 
only the data pertaining to the adults were extracted 
and analyzed. Another randomized study evaluated 
an echocardiographic protocol in 29 patients and a 
lung water protocol in 50 patients.35 Outcomes were 
reported exclusively for the lung water protocol, and 
only the data for those 50 patients were included in 
the meta-analysis.
Most of the studies were conducted in the United 
States (Table 1). The control fluid was lactated 
Ringer’s in all but one study.
Fluid protocols differed according to study design. 
In the randomized studies, test fluids were adminis-
tered early to every patient, in all cases within the 
first 12 hours. Among the nonrandomized studies, 
by contrast, albumin was commenced only after 8 to 
12 hours as rescue therapy for the difficult cases with 
observed excessive fluid requirements.
Randomized Study Quality
The quality of the randomized studies was generally 
poor. These were small, mostly old studies with a high 
risk of bias. The total numbers of patient in these four 
studies ranged from 18 to 50 (Table 1). Three of the 
four were published more than 30 years ago. Only 
one was conducted at more than one center.36
Small size rendered these studies more vulner-
able to chance imbalances in baseline risk of poor 
outcome, despite randomization. In the one multi-
center study,36 mean %TBSA burned and proportion 
of patients with inhalation injury were both higher 
in the albumin group (Table 2). While neither dif-
ference, taken singly, reached statistical significance, 
predicted mortality at baseline accounting for both 
%TBSA burned and inhalation injury41 was signifi-
cantly higher in the albumin group (P = .011). No 
statistical adjustment was applied for this imbalance. 
In another study,35 mean %TBSA burned was 16.3% 
higher in the albumin than control group (Table 2); 
however, that difference was not statistically signifi-
cant (P = .14).
In one each of the four included randomized stud-
ies, patients were assigned to treatment group by 
computer-generated randomization list,36 random 
number table,35 hospital number33, and an unspeci-
fied method.34 Allocation concealment was accom-
plished through the use of sequentially numbered 
sealed opaque envelopes in the multicenter study.36 
Measures taken to ensure allocation concealment 
were unspecified for the remaining studies. The mul-
ticenter study was unblinded. The use of blinding, if 
any, was unspecified for the other studies.
135 candidate reports
identified and screened
96 reports excluded after examination
28 review article
11 animal study
8 hypoalbuminemia study
7 editorial/letter/commentary
7 meta-analysis
6 pediatric study
5 no control
4 no outcome data
4 not purified albumin
3 albumin supplementation study
3 case report/series
3 guidelines
3 survey
2 ineligible control
2 unadjusted for imbalance
Reports Reason Excluded
104 reports retrieved
and examined in detail
8 studies included
(4 randomized +
4 nonrandomized)
31 reports excluded after screening
8 review article
3 animal study
3 commentary
3 no outcome data
2 hypoalbuminemia study
2 ineligible control
2 meta-analysis
2 pediatric study
2 survey
1 albumin supplementation study
1 case report
1 guidelines
1 no control
Reports Reason Excluded
Figure 1. Study selection process.
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Nonrandomized Study Quality
Published from 2007 to 2012, the four nonrandomized 
studies accounted for 81.2% of the total patients in the 
meta-analysis (Table 1). Thus, these studies were more 
recent and far larger than their randomized counter-
parts. They were, however, limited at least in part by ret-
rospective design. Two were retrospective case–control 
studies.37,38 The other two compared patients before vs 
after the institution of a new fluid protocol calling for the 
use of 5% albumin in difficult-to-resuscitate patients.39,40 
In one of those two, data were prospectively collected 
for consecutive patients after the switch to the new 
protocol.39 Otherwise the prospective vs retrospective 
design of the two before–after studies was unspecified.
Table 2. Patient characteristics
Study
Age (yr),  
Mean ± SD
%TBSA Burned,  
Mean ± SD
Inhalation Injury,  
N (%)
Albumin Control Albumin Control Albumin Control
Randomized
Recinos et al (1975)33 37.4 ± 23.3 50.0 ± 24.7 56.8 ± 16.7 57.0 ± 20.4 — —
Jelenko et al (1979)34 47.0 ± 14.8 41.5 ± 21.0 44.0 ± 14.8 49.2 ± 25.3 6 (85.7) 12 (100.0)
Goodwin et al (1983)35 29.0 ± 8.0 27.0 ± 9.0 50.0 ± 20.0 43.0 ± 12.0 0 (0.0) 0 (0.0)
Cooper et al (2006)36 36.0 ± 23.4 31.0 ± 17.1 39.0 ± 23.4 32.0 ± 9.8 12 (63.2) 11 (47.8)
Nonrandomized
Cochran et al (2007)37 37.9 ± 21.2 35.9 ± 21.0 42.3 ± 18.4 39.9 ± 16.6 52 (51.5)† 18 (17.8)
Dulhunty et al (2008)38‡ 37.5 ± 16.1 35.7 ± 14.3 41.0 ± 15.6 44.0 ± 21.9 22 (61.1) 27 (61.4)
Ennis et al (2008)39 25.0 ± 5.0§ 28.0 ± 8.0 52.0 ± 17.0 50.0 ± 17.0 20 (35.7) 26 (41.9)
Park et al (2012)40 41.0 ± 19.0 43.0 ± 18.0 38.0 ± 18.0 39.0 ± 18.0 20 (32.8) 41 (41.8)
† P < .001 vs control.
‡Reported albumin and control patient characteristic data for this study correspond respectively to poor responders who were the predominant albumin recipi-
ents and responders who received comparatively little albumin. Poor responders were defined as patients with fluid requirements at 8 hours greater than one-third 
the 24 hours Parkland volume.
§P = .021 vs control.
Table 1. Study characteristics
Study Locale Centers Patients Resuscitation Fluids Compared
Randomized
Recinos et al (1975)33 United States 1 18 2.3% albumin in LR vs LR starting within <12 hr to maintain 
30–50 ml·hr−1 urine output
Jelenko et al (1979)34 United States 1 19 1.25% albumin in hypertonic crystalloid vs LR or hypertonic 
crystalloid starting within 4.5 ± 2.9 hr (mean ± SD) to maintain 
60–100 mm Hg MAP and 30–50 ml·hr−1 urine output
Goodwin et al (1983)35 United States 1 50 2.5% albumin in LR vs LR starting within 4 hr to stabilize vital 
signs and maintain 30–50 ml·hr−1 urine output
Cooper et al (2006)36 Canada or United 
States
5 42 5% albumin plus LR vs LR starting within 12 hr to ABA- 
recommended resuscitation endpoints
Nonrandomized
Cochran et al (2007)37 United States 1 202 5% albumin if fluid requirement after 12 hr > 2 × Parkland calculated 
rate + LR vs LR to maintain 30–50 ml·hr−1 urine output
Dulhunty et al (2008)38 Australia 1 80 Albumin as main colloid usually if fluid use after 8 hr > one-third 
of Parkland 24 hr requirement primarily for hypotension 
(<60 mm Hg MAP) or oliguria (<0.5 ml·kg−1·hr−1 urine 
output) vs Hartmann’s solution or normal saline
Ennis et al (2008)39 United States 1 118 5% albumin starting at 12–18 hr if projected 24 hr resuscitation 
requirement >6 ml·kg−1 per %TBSA burned + LR vs LR
Park et al (2012)40 United States 1 159 5% albumin instead of LR starting at 12 hr if estimated 24 hr 
fluid need ≥6 ml·kg−1per %TBSA burned vs 4 ml·kg−1 LR per 
%TBSA burned
ABA, American Burn Association; LR, lactated Ringer’s; MAP, mean arterial pressure.
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Both retrospective case–control studies exhib-
ited significant baseline risk imbalances. In one,37 
inhalation injury was 2.9-fold more frequent in the 
albumin group (Table 2). In the other,38 baseline 
APACHE II score was higher in the albumin group. 
In both studies, results were adjusted for baseline 
imbalance using multivariate logistic regression. The 
groups differed slightly but significantly by age in 
one before–after study (Table 2).39
Mortality
Data on mortality were available for all four ran-
domized studies and three of the four nonrandom-
ized studies (Figure 2). Twenty-nine deaths occurred 
in the randomized studies and 90 in the nonran-
domized studies. In one retrospective case–control 
study with nearly three times the frequency of inha-
lation injury among albumin as control patients,37 
crude mortality was higher among albumin recipi-
ents. However, multivariate adjustment indicated a 
 significant decrease in the odds of death associated 
with albumin administration for that study.
The pooled OR showed lower odds of death among 
albumin recipients across all seven studies (Figure 2), 
although the difference was not statistically significant. 
No publication bias could be detected (P = .47). There 
was, however, substantial and significant heterogeneity 
(Figure 2). The heterogeneity could not be attributed 
to study design per se, since the OR for mortality did not 
differ significantly between the randomized and non-
randomized studies (P = .11). Rather, the heterogene-
ity was confined exclusively to the randomized studies 
(I2, 62.0%; CI, 0.0–87.2%; P = .048) and was absent 
from the nonrandomized studies (I2, 0.0%; CI, 0.0–
83.9%; P = 0.52).
One potential explanation for the heterogene-
ity was the above discussed evidence of unadjusted 
excess baseline risk among albumin recipients in two 
randomized studies.35,36 In both studies, the mortal-
ity of the albumin group was markedly elevated (OR, 
4.12 and 5.76); whereas, in all five of the other stud-
ies mortality was lower in the albumin group, and 
quantitatively the OR for mortality fell within the 
narrow range of 0.23 to 0.50. In a sensitivity analy-
sis, exclusion of the two imbalanced studies abol-
ished overall heterogeneity (I2, 0.0%; CI, 0.0–45.5%; 
P = .82). Furthermore, in that sensitivity analysis 
encompassing two randomized and three nonran-
domized studies, albumin administration was asso-
ciated with significantly reduced mortality (pooled 
OR, 0.34; 0.19–0.58; P < .001).
Mortality
Study Albumin Contro Ol R (CI) % Weight
Events Total Events Total
Randomized
Recinos et al (1975)33 2 9 5 9 0.23 (0.03-1.77) 11.2
Jelenko et al (1979)34 1 7 3 1 02 .50 (0.04-6.02) 8.9
Goodwin et al (1983)35 11 25 3 2 55 .76 (1.36-24.4) 15.3
Cooper et al (2006)36 3 19 1 23 4.12 (0.39-43.4) 9.6
Subtotal 17 60 12 69 1.41 (0.27-7.38) 45.0
Nonrandomized
Cochran et al (2007)37 19 101 11 101 0.25 (0.07-0.89)† 16.6
Ennis et al (2008)39 10 56 19 62 0.49 (0.21-1.18) 19.8
Park et al (2012)40 5 61 26 9 08 .25 (0.09-0.68) 18.6
Subtotal 34 218 56 261 0.34 (0.19-0.61) 55.0
Total 51 278 68 330 0.63 (0.25-1.63) 100.0
Heterogeneity: I2, 66.0% (CI, 23.8-84.8%); P = .007
Randomized vs. nonrandomized:
ROR, 4.17 (CI, 0.72-24.1); P = .11
†Adjusted by multivariate
logistic regression
Favors ControlFavors Albumin
OR (CI)
0.1 1 10
Figure 2. Mortality after burn shock resuscitation with albumin infusion. Data points for individual studies scaled in propor-
tion to meta-analytic weight. Error bars depict CI. CI, 95% confidence interval; OR, odds ratio; ROR, ratio of odds ratios.
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Morbidity
The most frequently reported forms of morbid-
ity were compartment syndrome of the abdomen 
or extremities (Figure 3), respiratory complica-
tions (Figure 4), and renal dysfunction (Figure 5). 
Thirty-eight total cases of compartment syndrome 
were reported among two randomized and three 
nonrandomized studies. The albumin group expe-
rienced a marked relative decrease of 81% in the 
odds of compartment syndrome (pooled OR, 0.19; 
P < .001). The magnitude of the effect did not dif-
fer between the randomized and nonrandomized 
Compartment Syndrome
Study Albumin Contro Ol R (CI) % Weight
Events Total Events Total
Randomized
Jelenko et al (1979)34 0 7 10 12 0.02 (0.00-0.38) 8.4
Cooper et al (2006)36 1 19 2 23 0.58 (0.05-6.98) 13.0
Subtotal 1 26 12 3 05 .11 (0.00-3.75) 21.4
Nonrandomized
Dulhunty et al (2008)38 —† 68 —† 12 0.06 (0.01-0.50) 17.0
Ennis et al (2008)39 3 56 10 6 02 .29 (0.08-1.13) 33.9
Park et al (2012)40 2 61 10 9 08 .30 (0.06-1.41) 27.7
Subtotal 5 185 20 172 0.22 (0.09-0.55) 78.6
Total 6 211 32 207 0.19 (0.07-0.50) 100.0
Heterogeneity: I2, 19.3% (CI, 0.0-83.2%); P = .29
Randomized vs. nonrandomized:
ROR, 0.50 (CI, 0.01-19.2); P = .71
†Adjusted OR (CI) reported
but not numbers of events
Favors
ControlFavors Albumin
OR (CI)
0.10.010.001 1 10
Figure 3. Compartment syndrome of the abdomen or extremities after burn shock resuscitation with albumin infusion. 
Graphic conventions as in Figure 2. CI, 95% confidence interval; OR, odds ratio; ROR, ratio of odds ratios.
Respiratory Complications
Study Albumin Contro Ol R (CI) % Weight
Events Total Events Total
Randomized
Recinos et al (1975)33 1 9 3 9 0.25 (0.02-3.04) 15.4
Jelenko et al (1979)34 0 7 6 1 02 .07 (0.00-1.42) 11.7
Goodwin et al (1983)35 5 25 1 25 6.00 (0.65-55.7) 17.6
Cooper et al (2006)36 2 19 2 23 1.24 (0.16-9.71) 19.2
Subtotal 8 60 12 6 09 .72 (0.12-4.38) 63.9
Nonrandomized
Park et al (2012)40 12 61 40 98 0.36 (0.17-0.75) 36.1
Total 20 121 52 167 0.58 (0.17-1.99) 100.0
Heterogeneity: I2, 51.2% (CI, 0.0-82.1%); P = .084
Randomized vs. nonrandomized:
ROR, 2.03 (CI, 0.29-14.3); P = .48
Favors ControlFavors Albumin
OR (CI)
0.10.01 1 10
Figure 4. Respiratory complications after burn shock resuscitation with albumin infusion. Graphic conventions as in Figure 2. 
CI, 95% confidence interval; OR, odds ratio; ROR, ratio of odds ratios.
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studies (P = .71), and there was no evidence of het-
erogeneity (P = .29) or publication bias (P = .28).
Albumin infusion was accompanied by reduced odds 
of respiratory complications, renal dysfunction, need 
for escharotomy or fasciotomy, tissue necrosis, sepsis, 
cardiovascular complications, edema, hypoproteinemia, 
local infection, and gastrointestinal and central ner-
vous system complications (Figures 4 and 5; Table 3). 
In most instances, these differences were neverthe-
less not statistically significant. Only gastrointestinal 
and central nervous system complications, reported in 
a single randomized study, were significantly reduced 
by albumin.
DISCUSSION
This is the first meta-analysis focused solely on the 
effects of albumin for burn shock resuscitation, the 
first to investigate morbidity in addition to mortality, 
the first to include data from nonrandomized as well as 
randomized controlled studies, and the first to address 
potential biases. Among all included studies, albumin 
infusion was commenced within the first 24 hours after 
burn injury. The meta-analysis suggests that, based on 
the totality of currently available evidence, acute burn 
shock resuscitation with albumin may reduce mortality 
and compartment syndrome.
Renal Dysfunction
Study Albumin Contro Ol R (CI) % Weight
Events Total Events Total
Randomized
Recinos et al (1975)33 0 9 4 9 0.06 (0.00-1.43) 13.6
Cooper et al (2006)36 3 19 3 23 1.25 (0.22-7.05) 30.2
Subtotal 3 28 7 32 0.38 (0.02-6.57) 43.8
Nonrandomized
Dulhunty et al (2008)38 —† 68 —† 12 0.11 (0.01-0.84) 24.9
Park et al (2012)40 2 61 5 98 0.63 (0.12-3.36) 31.3
Subtotal 2 129 5 110 0.29 (0.05-1.59) 56.2
Total 5 157 12 142 0.37 (0.10-1.33) 100.0
Heterogeneity: I2, 37.8% (CI, 0.0-78.7%); P = .19
Randomized vs. nonrandomized:
ROR, 1.30 (CI, 0.05-36.0); P = .88
†Adjusted OR (CI) reported
but not numbers of events
Favors
ControlFavors Albumin
OR (CI)
0.10.01 1
Figure 5. Renal dysfunction after burn shock resuscitation with albumin infusion. Graphic conventions as in Figure 2. 
CI, 95% confidence interval; OR, odds ratio; ROR, ratio of odds ratios.
Table 3. Less frequently reported complications
Complication Studies
Albumin Control OR (CI)
Events Total Events Total
Escharotomy or 
fasciotomy
334,39,40 55 124 73 172 0.60 (0.13–2.77)
Tissue necrosis 233,39 15 65 20 71 0.78 (0.36–1.71)
Sepsis 233,36 4 28 13 32 0.26 (0.06–1.10)
Cardiovascular 233,36 5 28 9 32 0.67 (0.12–3.69)
Edema 136 1 19 5 23 0.20 (0.02–1.89)
Hypoproteinemia 136 0 19 1 23 0.38 (0.01–9.99)
Local infection 136 4 19 7 23 0.61 (0.15–2.51)
Gastrointestinal 134 0 7 11 12 0.01 (0.00–0.24)
CNS 134 1 7 12 12 0.01 (0.00–0.26)
CI, 95% confidence interval; OR, odds ratio.
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At the same time, the meta-analysis indicated 
important weaknesses in the existing evidence. The 
quality of available randomized studies is poor, and 
retrospective design is a limitation of some available 
nonrandomized studies. The numbers of patients 
with available data for other types of complications 
were far smaller than for compartment syndrome, 
and hence the meta-analysis may have been under-
powered to detect additional effects on morbidity. It 
is noteworthy that the odds of all 11 types of com-
plications evaluated besides compartment syndrome 
(Figures 4 and 5; Table 3) were lower in the albumin 
group, although the difference was only significant 
for two complication types based on data from a 
single study. All these weaknesses highlight the need 
for additional trials, a need that has previously been 
recognized.7,42
Among all seven studies with data no overall effect 
of albumin on mortality could be detected. That 
result needs to be interpreted with caution because 
of the presence of marked heterogeneity. On inves-
tigation that heterogeneity could be ascribed to dis-
proportionate baseline risk in the albumin group of 
two randomized studies. Heterogeneity could be 
eliminated by excluding those two studies, with the 
result that albumin infusion was associated with a sig-
nificant 64% relative decrease in the odds of death 
(OR, 0.34).
Baseline risk imbalances were also evident in two 
of the nonrandomized studies; however, the investi-
gators used multivariate statistical analysis to adjust 
for imbalance. In one retrospective case–control 
study,37 the largest study of the meta-analysis, there 
was nearly three times the frequency of inhalation 
injury among albumin as control patients, and crude 
mortality was higher among albumin recipients. 
Inhalation injury is an important risk factor for mor-
tality in burned patients.41,43,44 Adjustment for the 
imbalance revealed a 75% relative decrease in mortal-
ity odds for that study (OR, 0.25).
More than 80% of all patients were derived from 
the included nonrandomized studies, and so the 
meta-analysis borrowed major strength from those 
studies. Thus, there was a clear advantage to includ-
ing nonrandomized studies. This advantage was not 
gained at the cost of heterogeneity, inasmuch as 
there was in no case any significant effect size differ-
ence between the randomized and nonrandomized 
studies (Figures 2–5). This finding is consistent with 
numerous large-scale empirical studies demonstrat-
ing agreement between randomized and nonran-
domized studies.45–48
Mortality from burn injuries is now at historically 
low levels,8 and thus more attention is being focused 
on associated morbidity. The recent renewed interest 
in the use of albumin has been driven by the desire 
to reduce morbidity related to the large quantities 
of resuscitation fluid administered to burn patients 
in the first 24 hours. Aggressive fluid therapy can 
escalate the massive edema in both burned and non-
burned tissue occurring after burn injury.49 Edema 
leads to tissue hypoxia and increased tissue pressure. 
Increased interstitial pressure in burned soft tissue 
compartments often necessitates escharotomy or 
even fasciotomy.49 ACS is an extreme example of 
massive edema, which can be life-threatening.50,51 
Compartment syndrome can also occur in unburned 
limbs, requiring fasciotomies. In all five studies with 
data on either abdominal or extremity compartment 
syndrome, albumin use was consistently associated 
with a marked decrease in this complication. The 
overall pooled results showed an 81% relative odds 
decrease for compartment syndrome in the albumin 
group patients. This observation is in accord with a 
randomized trial of 31 severely burned patients com-
paring FFP and lactated Ringer’s as the resuscitation 
fluids.52 There was a significantly greater increase in 
intraabdominal pressure among patients assigned to 
the crystalloid protocol, and all but one patient of 
15 in that group exceeded the 25-mm Hg pressure 
threshold associated with complications. By con-
trast, 14 of the 16 patients in the FFP group did not 
exceed the threshold.
A 1998 Cochrane meta-analysis exclusively of ran-
domized trials suggested increased mortality attrib-
utable to albumin among critically injured patients, 
including those with burns.53 That meta-analysis was 
widely criticized by burn specialists54–57 and could 
not be reproduced, either with respect to critically 
injured patients generally or burn patients spe-
cifically, in a far larger subsequent meta-analysis.58 
Importantly, no excess mortality related to albumin 
has been found in three subsequent large-scale ran-
domized trials of critically injured patients.59–61
The explanation for the disparity was shown to 
be that the Cochrane meta-analysis was limited to a 
small, biased subset of eligible randomized trials.62 
With regard to burns in particular, the latest 2011 
update of the Cochrane meta-analysis includes four 
randomized studies with 205 total patients under-
going burn shock resuscitation or postburn albumin 
supplementation and continues to suggest an almost 
3-fold increase in the odds of death among patients 
receiving albumin.63 However, the Cochrane inves-
tigators neglected to include two trials satisfying 
their eligibility criteria and showing either reduced 
mortality among albumin recipients33 or no effect.64 
With inclusion of the two omitted trials a significant 
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effect on mortality can no longer be demonstrated. 
Furthermore, no attempt was made in that meta-
analysis to deal with the baseline risk imbalances 
favoring the control group in two of the included 
studies.35,36
In a recent Brazilian study of a hospital information 
system database, albumin was administered to 4% of 
39,684 patients with moderate or major burns.65 
Although an association between albumin usage 
and increased mortality was claimed, no assessment 
was reported on the comparative baseline %TBSA 
burned or frequency of inhalation injury between 
albumin recipients and nonrecipients. In large inten-
sive care unit studies, albumin was reserved for the 
most severely injured patients,66,67 and the Brazilian 
study was likely subject to similar allocation bias. 
Accordingly, that study was excluded from the cur-
rent meta-analysis.
A major issue regarding burn shock resuscitation 
with colloids is whether because of the early transient 
increase in capillary permeability their use could 
contribute to edema formation. In a comprehensive 
review of the burn edema process, Demling con-
cluded that in virtually all experimental studies, using 
both protein and nonprotein colloids, there was a 
decrease in nonburned skin edema and no increase 
in burn wound edema.49 Increased vascular perme-
ability appears to be only a phenomenon of the first 
few hours after a burn injury.68 Beginning about 8 to 
12 hours postburn, decreased plasma oncotic pres-
sure resulting from depleted plasma protein levels 
contributes to fluid movement into the tissues.
In the included nonrandomized studies, albumin 
was administered as rescue therapy for the most 
difficult-to-resuscitate patients, starting from 8 to 
12 hours after the burn injury. Albumin use was 
begun even earlier in the included randomized stud-
ies. According to the most recent recommendations 
of the American Burn Association, one option is to 
administer colloid-containing fluids between 12 and 
24 hours postinjury to decrease overall fluid require-
ments during acute burn shock resuscitation.69
Transient increase in vascular permeability dur-
ing the first hours after thermal injury may provide 
a mechanistic basis for favoring a delay before albu-
min infusion until 8 to 12 hours.68 Nevertheless, 
that approach, as exemplified by the included non-
randomized studies, was not associated in this meta-
analysis with superior outcomes as compared with 
the included randomized studies in which albumin 
administration was commenced earlier. The meta-
analysis may have been underpowered to detect such 
a difference, and additional data would be needed to 
resolve this question.
Use of albumin in burned patients was first 
described more than 70 years ago among combat 
casualties of Pearl Harbor.70 Yet, despite clinical use 
in burns for decades, the optimal timing, dose, and 
patient population for albumin use remain unclear. 
As demonstrated in this meta-analysis, the current 
available evidence suggests that albumin can improve 
outcomes of burn shock resuscitation. However, the 
scope and quality of current evidence are limited, 
and new adequately powered, preferably multicenter 
clinical trials should be conducted.
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